Episode 400: 408. CME Obesity and MASH

Episode 400: 408. CME Obesity and MASH

  • GLP1 drugs work but they likely need lifestyle modifications


  • No convincing evidence GLP1 cause thyroid cancer in humans BUT contraindication if family history exist


  • Stopping therapy usually results in weight gain


  • Insurance coverage for weight loss is limited and variable


  • Semaglutide for type 2 diabetes max dose is 2.0 mg weekly Semaglutide for weight loss has a goal dose of 2.4 mg weekly
  • Diagnose steatotic liver disease with imaging and 1 metabolic risk factor (or biopsy)


  • After diagnosis check FIB-4:
    • Low risk, continue to monitor with FIB-4 every 2-3yrs
    • Intermediate risk, order VCTE and consider referral if >F1
    • High risk order a VCTE and referral (20% end with SLD)


  • 2 FDA approved medications for liver fibrosis are not cheap, expect insurance push back


Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(401)

Populärt inom Hälsa

husmodern-med-amanda-schulman
somna-med-henrik
rss-bara-en-till-om-beroende-medberoende
rss-jossan-nina
inga-beiga-morsor
rss-vuxna-pa-latsas
not-fanny-anymore
rss-viktmedicinpodden
sexnoveller-deluxe
angestpodden
rss-hos-psykologen
sova-med-dan-horning
rss-ronden
johannes-hansen-podcast
sa-in-i-sjalen
rss-basta-livet
rss-lattsamt-med-kp
dodsdomar
rss-lyckopodden
till-sangs